Tyson Foods to close major Nebraska beef plant amid cattle shortage - WSJ
TESARO, Inc., a subsidiary of GSK plc (LSE/NYSE:GSK), has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, according to a press release statement filed with the SEC. The action, announced Thursday, alleges that AnaptysBio has materially breached the existing license agreement related to the oncology treatment Jemperli (dostarlimab).
GSK stated that the alleged breach entitles TESARO to terminate the current license agreement, obtain a perpetual and irrevocable license to dostarlimab, and reduce the royalties and milestone payments due to AnaptysBio by 50%.
The legal action follows allegations from AnaptysBio that TESARO has not fulfilled certain requirements of the March 2014 license agreement and that AnaptysBio intends to revoke TESARO’s license for dostarlimab. In the filing, GSK and TESARO stated they believe these allegations are without merit.
Jemperli is currently approved in more than 35 countries for use in certain endometrial cancers. GSK and TESARO have reported growth for Jemperli, citing label expansions in the United States and European Union. Clinical trials are ongoing to evaluate dostarlimab in additional cancer indications, including rectal, colon, and head and neck cancers.
The information is based on a press release statement included in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.